Corvus Pharmaceuticals, Inc.

CRVSSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1626971

Concept	FY2025	FY2024	FY2023	FY2021	FY2020
Research and Development Expense	$16.5M	$24.5M	$29.1M	$31.8M	$38.6M
Operating Expenses	$23.4M	$32.6M	$38.6M	$43.8M	$49.2M
Operating Income (Loss)	-$23.4M	-$32.6M	-$38.6M	-$43.8M	-$49.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	-$6.0M	-$46.9M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$27.0M	-$41.3M	-$43.2M	-$6.0M	-$46.9M
Earnings Per Share, Basic	-$0.56	-$0.89	-$1.03	-$0.20	—
Earnings Per Share, Diluted	-$0.56	-$0.89	-$1.03	-$0.20	—

Concept	FY2025	FY2024	FY2023	FY2021	FY2020
Assets	$68.9M	$45.6M	$68.2M	$109.5M	$83.6M
Assets, Current	$54.4M	$28.0M	$43.7M	$71.3M	$79.3M
Cash and Cash Equivalents, at Carrying Value	$8.7M	$12.6M	$13.2M	$63.5M	$5.2M
Accounts Receivable, after Allowance for Credit Loss, Current	$75.0K	$26.0K	$588.0K	—	—
Liabilities	$36.3M	$6.9M	$12.1M	$12.3M	$12.5M
Liabilities, Current	$35.4M	$6.9M	$10.8M	$9.7M	$10.2M
Accounts Payable, Current	$2.6M	$1.5M	$2.0M	$1.6M

Concept	FY2025	FY2024	FY2023	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$23.9M	-$27.0M	-$36.7M	-$34.8M	-$41.0M
Net Cash Provided by (Used in) Investing Activities	$15.5M	-$23.3M	$21.6M	$44.8M	-$30.2M
Net Cash Provided by (Used in) Financing Activities	$7.9M	$0.00	$62.2M	$1.3M	$65.3M
Payments to Acquire Property, Plant, and Equipment	$34.0K	$269.0K	$5.0K	$76.0K	$355.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)